drugset / Trial / NCT03887650

LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs

NCT03887650 ↗

Phase 4 Completed 90 enrolled Hartford Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This will be a single-center, prospective, randomized controlled cross-sectional study comparing interscalene brachial plexus block with liposomal bupivacaine versus bupivacaine with epinephrine and PF dexamethasone in patients undergoing primary shoulder arthroplasty. Primary endpoint will be total opioid consumption in the first three post-operative days.

Timeline

Start
2019-03-11
Primary completion
2022-01-11
Completion
2022-03-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 10 ml Other
Comparator Bupivacaine Other / unclassified 20 ml Other
Comparator Bupivacaine Other / unclassified 133 mg Other
Comparator Dexamethasone Small molecule 5 mg Other
Comparator Epinephrine Other / unclassified 5 ug Other

Indications